{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:48:54Z","timestamp":1765349334745,"version":"3.46.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Phosphodiesterase-5 (PDE5) inhibitors, commonly prescribed for erectile dysfunction, may exhibit immunomodulatory properties by reducing myeloid-derived suppressor cell activity and enhancing T-cell responses. This study evaluated the association between PDE5 inhibitor use and overall survival (OS) in male-predominant solid organ malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Male-predominant solid tumors were identified using male-to-female incidence ratio \u22653:1 in SEER database: prostate, bladder, colon, esophageal, hypopharyngeal, laryngeal, tonsillar, and testicular cancers. Using the TriNetX Research Network, we compared male patients prescribed PDE5 inhibitors within 6 months of cancer diagnosis to those without PDE5 exposure. Propensity score matching (PSM) was performed on demographic, clinical, and oncologic variables. OS was assessed in a combined pan-cancer cohort, stratified by overall stage, and subgroups of included cancers. Kaplan-Meier survival analyses were conducted for 1-, 3-, and 5-year OS from diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, 108,630 patients were included in each arm of the pan-cancer analysis. PDE5 inhibitor exposure was associated with significantly improved OS at 1, 3, and 5 years compared with controls (5-year OS 93.8% vs 86.6%; HR, 0.42 [95% CI, 0.41\u20130.44]). Stratified analyses demonstrated significantly improved OS across all four stages, with hazard ratios ranging from 0.40 to 0.57. Subgroup analyses by tumor site likewise showed statistically significant improvement in OS for every included cancer type, with hazard ratios ranging from 0.35 to 0.70.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PDE5 inhibitor use was consistently associated with improved OS across all male-predominant cancers, including in stage-stratified analyses. These findings support further investigation into the potential role of PDE5 inhibitors in cancer outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1720304","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:45:00Z","timestamp":1765349100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study"],"prefix":"10.3389","volume":"15","author":[{"given":"Daniel","family":"Uralov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Samarah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika S.","family":"Walia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Aweeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal U.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Parvesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Briskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric V.","family":"Mastrolonardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Luginbuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623436","article-title":"Targeting myeloid cells to improve cancer immune therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157537","article-title":"Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.3.1232","article-title":"l -arginine consumption by macrophages modulates the expression of CD3\u03b6 Chain in T lymphocytes","volume":"171","author":"Rodriguez","year":"2003","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors \u2013 pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1716","article-title":"Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Califano","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1816","article-title":"Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma","volume":"28","author":"Luginbuhl","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","article-title":"Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression","volume":"16","author":"Serafini","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e00173","DOI":"10.14309\/ctg.0000000000000173","article-title":"The association between phosphodiesterase-5 inhibitors and colorectal cancer in a national cohort of patients","volume":"11","author":"Sutton","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e179292","DOI":"10.1172\/jci.insight.179292","article-title":"Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma","volume":"9","author":"Gross","year":"2024","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e006493","DOI":"10.1136\/jitc-2022-006493","article-title":"T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s42003-025-07519-9","article-title":"Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription","volume":"8","author":"Zhang","year":"2025","journal-title":"Commun Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1038\/s41467-020-17028-4","article-title":"Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"key":"B18","first-page":"41","article-title":"Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC","volume":"7","author":"Lin","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1431082","DOI":"10.1080\/2162402X.2018.1431082","article-title":"Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity","volume":"7","author":"Tai","year":"2018","journal-title":"OncoImmunology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.5534\/wjmh.220063","article-title":"Phosphodiesterase-5 inhibitor use in robot assisted radical prostatectomy patients is associated with reduced risk of death: A propensity score matched analysis of 1,058 patients","volume":"41","author":"Lee","year":"2023","journal-title":"World J Mens Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1326440","DOI":"10.1080\/2162402X.2017.1326440","article-title":"Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Ta dalafil in patients with metastatic Melanoma (TaMe)","volume":"6","author":"Hassel","year":"2017","journal-title":"OncoImmunology"},{"key":"B23","doi-asserted-by":"crossref","unstructured":"Pantziarka\n              P\n            \n            \n              Sukhatme\n              V\n            \n            \n              Crispino\n              S\n            \n            \n              Bouche\n              G\n            \n            \n              Meheus\n              L\n            \n            \n              Sukhatme\n              VP\n            \n          \n          Repurposing drugs in oncology (ReDO)\u2014selective PDE5 inhibitors as. ecancer\n          \n          2018","DOI":"10.3332\/ecancer.2018.824"},{"key":"B24","unstructured":"National Cancer Institute\n          Surveillance, Epidemiology, and End Results (SEER) Program"},{"key":"B25","unstructured":"National Cancer Institute\n          National Cancer Care Registry (NCCR)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1720304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:45:05Z","timestamp":1765349105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1720304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1720304"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1720304","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1720304"}}